{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:00:12Z","timestamp":1790395212942,"version":"4.1.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004829","name":"Department of Science and Technology of Sichuan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004829","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.biopha.2020.110888","type":"journal-article","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T23:38:49Z","timestamp":1603237129000},"page":"110888","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":141,"special_numbering":"C","title":["A review on development of MUC1-based cancer vaccine"],"prefix":"10.1016","volume":"132","author":[{"given":"Tong","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhong","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2020.110888_bib0005","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.biopha.2020.110888_bib0010","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/oxfordjournals.jbchem.a133724","article-title":"Isolation and characterization of mucin-like glycoprotein in human milk fat globule membrane","volume":"91","author":"Shimizu","year":"1982","journal-title":"J. Biochem."},{"key":"10.1016\/j.biopha.2020.110888_bib0015","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/1097-0142(19910801)68:3<574::AID-CNCR2820680322>3.0.CO;2-B","article-title":"The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen","volume":"68","author":"Safi","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2020.110888_bib0020","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.1986.4.10.1542","article-title":"Comparison of circulating CA15-3 and carcinoembryonic antigen levels in patients with breast cancer","volume":"4","author":"Hayes","year":"1986","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2020.110888_bib0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00002371-199807000-00002","article-title":"Retroviral expression of MUC-1 human tumor antigen with intact repeat structure and capacity to elicit immunity in vivo","volume":"21","author":"Henderson","year":"1998","journal-title":"J. Immunother."},{"key":"10.1016\/j.biopha.2020.110888_bib0030","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/sj.bjc.6604340","article-title":"Overexpression and altered glycosylation of MUC1 in malignant mesothelioma","volume":"98","author":"Creaney","year":"2008","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110888_bib0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/glycob\/10.5.439","article-title":"MUC1: the polymorphic appearance of a human mucin","volume":"10","author":"Hanisch","year":"2000","journal-title":"Glycobiology"},{"key":"10.1016\/j.biopha.2020.110888_bib0040","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1164\/ajrccm\/144.3_pt_2.S42","article-title":"Structure and biology of a carcinoma-associated mucin, MUC1","volume":"144","author":"Gendler","year":"1991","journal-title":"Am. Rev. Respir. Dis."},{"key":"10.1016\/j.biopha.2020.110888_bib0045","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jcb.240501117","article-title":"Altered glycosylation of mucin glycoproteins in colonic neoplasia","volume":"16G","author":"Kim","year":"1992","journal-title":"J. Cell. Biochem. Suppl."},{"key":"10.1016\/j.biopha.2020.110888_bib0050","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0968-0896(98)00092-3","article-title":"Effects of glycosylation on fragments of tumour associated human epithelial mucin MUC1","volume":"6","author":"Braun","year":"1998","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2020.110888_bib0055","doi-asserted-by":"crossref","first-page":"4981","DOI":"10.1002\/chem.200600144","article-title":"Synthesis and structural model of an alpha (2,6)-sialyl-t glycosylated MUC1 eicosapeptide under physiological conditions","volume":"12","author":"Dziadek","year":"2006","journal-title":"Chemistry"},{"key":"10.1016\/j.biopha.2020.110888_bib0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/vaccines4030025","article-title":"Immunological evaluation of recent MUC1 glycopeptide cancer vaccines","volume":"4","author":"Hossain","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.biopha.2020.110888_bib0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrc1251","article-title":"Mucins in cancer: protection and control of the cell surface","volume":"4","author":"Hollingsworth","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2020.110888_bib0070","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.6729450","article-title":"T and Tn, general carcinoma autoantigens","volume":"224","author":"Springer","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.biopha.2020.110888_bib0075","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/glycob\/cwi005","article-title":"Not core 2 beta 1,6-N-acetylglucosaminyltransferase-2 or -3 but -1 regulates sialyl-Lewis x expression in human precursor B cells","volume":"15","author":"Kikuchi","year":"2005","journal-title":"Glycobiology"},{"key":"10.1016\/j.biopha.2020.110888_bib0080","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1084\/jem.20112631","article-title":"Inducible colitis-associated glycome capable of stimulating the proliferation of memory CD4+ T cells","volume":"209","author":"Nishida","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.biopha.2020.110888_bib0085","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/glycob\/cws075","article-title":"MUC1 in human and murine mammary carcinoma cells decreases the expression of core 2\u03b2 1,6-N-acetylglucosaminyl transferase and \u03b2-galactoside \u03b12,3-sialyl transferase","volume":"22","author":"Solatycka","year":"2012","journal-title":"Glycobiology"},{"key":"10.1016\/j.biopha.2020.110888_bib0090","doi-asserted-by":"crossref","first-page":"44490","DOI":"10.1074\/jbc.M112.425827","article-title":"Cyclooxygenase-2 enzyme induces the expression of the \u03b1-2,3-sialyltransferase-3 (ST3Gal-I) in breast cancer","volume":"287","author":"Sproviero","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.110888_bib0095","first-page":"983","article-title":"ST6GAL1: a key player in cancer","volume":"18","author":"Garnham","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2020.110888_bib0100","first-page":"224","article-title":"Mucins in the pathogenesis of breast cancer: implications in diagnosis, prognosis and therapy","volume":"1815","author":"Mukhopadhyay","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.biopha.2020.110888_bib0105","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/sj.onc.1209976","article-title":"MUC1 is a novel regulator of ErbB1 receptor trafficking","volume":"26","author":"Pochampalli","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2020.110888_bib0110","doi-asserted-by":"crossref","first-page":"e28234","DOI":"10.1371\/journal.pone.0028234","article-title":"MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells","volume":"6","author":"Kosugi","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2020.110888_bib0115","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbrc.2004.02.072","article-title":"MUC1 can interact with adenomatous polyposis coli in breast cancer","volume":"316","author":"Hattrup","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2020.110888_bib0120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s40880-015-0007-9","article-title":"Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond","volume":"34","author":"Delaney","year":"2015","journal-title":"Chin. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110888_bib0125","doi-asserted-by":"crossref","first-page":"42248","DOI":"10.1074\/jbc.M111.297630","article-title":"MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-kappaB p65 and binding to cytokine promoters: importance of extracellular domain","volume":"286","author":"Cascio","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2020.110888_bib0130","doi-asserted-by":"crossref","first-page":"10413","DOI":"10.1158\/0008-5472.CAN-05-2474","article-title":"MUC1 oncoprotein blocks glycogen synthase kinase 3beta-mediated phosphorylation and degradation of beta-catenin","volume":"65","author":"Huang","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110888_bib0135","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1038\/sj.onc.1208738","article-title":"Muc1 affects c-Src signaling in PyV MT-induced mammary tumorigenesis","volume":"24","author":"Almasri","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.biopha.2020.110888_bib0140","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1189\/jlb.0604333","article-title":"MUC1 (CD227) interacts with lck tyrosine kinase in Jurkat lymphoma cells and normal T cells","volume":"77","author":"Mukherjee","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.biopha.2020.110888_bib0145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1615\/CritRevImmunol.v14.i3-4.40","article-title":"Cellular mucins: targets for immunotherapy","volume":"14","author":"Apostolopoulos","year":"1994","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.biopha.2020.110888_bib0150","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00262-004-0581-1","article-title":"Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer","volume":"54","author":"Ramanathan","year":"2005","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2020.110888_bib0155","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3892\/mmr.2014.2306","article-title":"MUC1 and maltosebinding protein recombinant fusion protein combined with Bacillus CalmetteGuerin induces MUC1specific and nonspecific antitumor immunity in mice","volume":"10","author":"Fang","year":"2014","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2020.110888_bib0160","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.imlet.2010.12.005","article-title":"Synergistic antitumor effects of Escherichia coli maltose binding protein and Bacillus calmette-Guerin in a mouse lung carcinoma model","volume":"136","author":"Zhang","year":"2011","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.biopha.2020.110888_bib0165","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.intimp.2016.02.006","article-title":"Pre-clinical toxicity and immunogenicity evaluation of a MUC1-MBP\/BCG anti-tumor vaccine","volume":"33","author":"Hu","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.biopha.2020.110888_bib0170","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/eji.200535490","article-title":"Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity","volume":"36","author":"Li","year":"2006","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.biopha.2020.110888_bib0175","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cmdc.201700646","article-title":"A synthetic MUC1 anticancer vaccine containing mannose ligands for targeting macrophages and dendritic cells","volume":"13","author":"Glaffig","year":"2018","journal-title":"Chem Med Chem."},{"key":"10.1016\/j.biopha.2020.110888_bib0180","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/(SICI)1097-0215(19990209)80:4<595::AID-IJC18>3.0.CO;2-B","article-title":"Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice","volume":"80","author":"Tempero","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110888_bib0185","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.4049\/jimmunol.166.11.6555","article-title":"Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection","volume":"166","author":"Soares","year":"2001","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2020.110888_bib0190","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1006\/jsre.1996.0264","article-title":"A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma","volume":"63","author":"Goydos","year":"1996","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.biopha.2020.110888_bib0195","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/(SICI)1097-0215(19980610)76:6<817::AID-IJC9>3.0.CO;2-0","article-title":"Anti-MUC1 class I restricted CTLs in metastatic breast cancer patients immunized with a synthetic MUC1 peptide","volume":"76","author":"Reddish","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110888_bib0200","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3816\/CLC.2001.n.018","article-title":"Phase I study of the BLP25(MUC1 peptide) liposomal vaccine for active specific immunotherapy in stage IIIB\/IV non-small-cell lung cancer","volume":"3","author":"Palmer","year":"2001","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.biopha.2020.110888_bib0205","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0022-5347(06)00494-0","article-title":"A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy","volume":"176","author":"North","year":"2006","journal-title":"J. Urol."},{"key":"10.1016\/j.biopha.2020.110888_bib0210","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00432-011-1003-3","article-title":"Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial","volume":"137","author":"Butts","year":"2011","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2020.110888_bib0215","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S1470-2045(13)70510-2","article-title":"START trial team, Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial","volume":"15","author":"Butts","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2020.110888_bib0220","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1471-2407-12-144","article-title":"LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial","volume":"12","author":"Schimanski","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2020.110888_bib0225","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1517\/14712598.2015.1088519","article-title":"Update on Mucin-1 immunotherapy in cancer: a clinical perspective","volume":"15","author":"Rivalland","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2020.110888_bib0230","first-page":"315","article-title":"Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model","volume":"58","author":"Rowse","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110888_bib0235","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1023\/A:1022260711583","article-title":"MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment","volume":"18","author":"Mukherjee","year":"2001","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.biopha.2020.110888_bib0240","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-065X.2008.00606.x","article-title":"Signaling defects in anti-tumor T cells","volume":"222","author":"Frey","year":"2008","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.biopha.2020.110888_bib0245","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-12-0275","article-title":"MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study","volume":"6","author":"Kimura","year":"2013","journal-title":"Cancer Prev. Res. (Phila)"},{"key":"10.1016\/j.biopha.2020.110888_bib0250","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/rmv.467","article-title":"Current developments in viral DNA vaccines: shall they solve the unsolved","volume":"15","author":"Rajcani","year":"2005","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.biopha.2020.110888_bib0255","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3892\/ol.2017.5717","article-title":"Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy","volume":"13","author":"Gong","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.biopha.2020.110888_bib0260","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3390\/vaccines3020390","article-title":"CpG oligonucleotides as cancer vaccine adjuvants","volume":"3","author":"Shirota","year":"2015","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.biopha.2020.110888_bib0265","first-page":"737","article-title":"Enhanced inhibitory effect of MUC1 gene vaccine on breast cancer growth by GM-CSF","volume":"20","author":"Yuan","year":"2004","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"10.1016\/j.biopha.2020.110888_bib0270","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1016\/j.vaccine.2016.04.045","article-title":"MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model","volume":"34","author":"Zhang","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.biopha.2020.110888_bib0275","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/sji.12633","article-title":"MUC1- and Survivin-based DNA Vaccine Combining Immunoadjuvants CpG and interleukin-2 in a bicistronic expression plasmid generates specific immune responses and antitumour effects in a murine colorectal carcinoma model","volume":"87","author":"Liu","year":"2018","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.biopha.2020.110888_bib0280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/1440-1681.12654","article-title":"Enhanced synergistic anti-Lewis lung carcinoma effect of a DNA vaccine harboring a MUC1-VEGFR2 fusion gene used with GM-CSF as an adjuvant","volume":"44","author":"Ruan","year":"2017","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.biopha.2020.110888_bib0285","first-page":"885","article-title":"A novel chimeric DNA vaccine: enhancement of preventive and therapeutic efficacy of DNA vaccine by fusion of Mucin 1 to a heat shock protein 70 gene","volume":"4","author":"Choi","year":"2011","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2020.110888_bib0290","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.imlet.2018.06.004","article-title":"Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect","volume":"200","author":"Liu","year":"2018","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.biopha.2020.110888_bib0295","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1016\/j.vaccine.2006.01.014","article-title":"A MUC1\/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice","volume":"24","author":"Snyder","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.biopha.2020.110888_bib0300","first-page":"332","article-title":"Survivin expression in head and neck squamous cell carcinomas is frequent and correlates with clinical parameters and treatment outcomes","volume":"6","author":"Munscher","year":"2018","journal-title":"Clin. Oral Investig."},{"key":"10.1016\/j.biopha.2020.110888_bib0305","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1007\/PL00006677","article-title":"MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines","volume":"48","author":"Acres","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2020.110888_bib0310","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/jgm.397","article-title":"Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer","volume":"5","author":"Rochlitz","year":"2003","journal-title":"J. Gene Med."},{"key":"10.1016\/j.biopha.2020.110888_bib0315","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10637-008-9187-3","article-title":"MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure","volume":"27","author":"Dreicer","year":"2009","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.biopha.2020.110888_bib0320","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S1470-2045(11)70259-5","article-title":"Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial","volume":"12","author":"Quoix","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2020.110888_bib0325","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(15)00483-0","article-title":"TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b\/3 trial","volume":"17","author":"Quoix","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2020.110888_bib0330","first-page":"232","article-title":"Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen","volume":"22","author":"Hillman","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2020.110888_bib0335","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1146\/annurev.iy.09.040191.001415","article-title":"The dendritic cell system and its role in immunogenicity","volume":"9","author":"Steinman","year":"1991","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.biopha.2020.110888_bib0340","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.tranon.2018.03.007","article-title":"Dendritic cell-based immunotherapy for solid tumors","volume":"11","author":"Jing","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.biopha.2020.110888_bib0345","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1159\/000011986","article-title":"Recurrences and relation to tumor growth potential and local immune response in node-negative advanced gastric cancer","volume":"56","author":"Maehara","year":"1999","journal-title":"Oncology"},{"key":"10.1016\/j.biopha.2020.110888_bib0350","first-page":"955","article-title":"A phase I\/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors","volume":"6","author":"Lepisto","year":"2006","journal-title":"Cancer Ther."},{"key":"10.1016\/j.biopha.2020.110888_bib0355","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-05-1574","article-title":"Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma","volume":"12","author":"Loveland","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2020.110888_bib0360","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00262-002-0317-z","article-title":"Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I\/II clinical trial","volume":"51","author":"Pecher","year":"2002","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2020.110888_bib0365","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/sj.cgt.7700961","article-title":"Phase I\/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA","volume":"13","author":"Kyte","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.biopha.2020.110888_bib0370","first-page":"3239","article-title":"Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand","volume":"60","author":"Mach","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110888_bib0375","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/mt.2010.289","article-title":"Intradermal vaccinations with RNA coding for TAA generate CD8+ and CD4+ immune responses and induce clinical benefit in vaccinated patients","volume":"19","author":"Rittig","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2020.110888_bib0380","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0145-2126(02)00002-4","article-title":"Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity","volume":"26","author":"Liu","year":"2002","journal-title":"Leuk. Res."},{"key":"10.1016\/j.biopha.2020.110888_bib0385","first-page":"3735","article-title":"Interleukin 18 transfection enhances antitumor immunity induced by dendritic cell-tumor cell conjugates","volume":"61","author":"Ju","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2020.110888_bib0390","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1186\/s12885-017-3859-3","article-title":"Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC","volume":"17","author":"Ge","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2020.110888_bib0395","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1158\/2326-6066.CIR-15-0189","article-title":"Tn-MUC1 DC vaccination of Rhesus macaques and a phase I\/II trial in patients with nonmetastatic castrate-resistant prostate cancer","volume":"4","author":"Scheid","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2020.110888_bib0400","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0022-1759(02)00298-3","article-title":"The epitope recognized by the unique anti-MUC1 monoclonal antibody MY.1E12 involves sialyl alpha 2-3galactosyl beta 1-3N-acetylgalactosaminide linked to a distinct threonine residue in the MUC1 tandem repeat","volume":"270","author":"Takeuchi","year":"2002","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.biopha.2020.110888_bib0405","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1039\/c3cs35470a","article-title":"The development of synthetic antitumour vaccines from mucin glycopeptide antigens","volume":"42","author":"Gaidzik","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biopha.2020.110888_bib0410","doi-asserted-by":"crossref","first-page":"7630","DOI":"10.1002\/anie.200501594","article-title":"A fully synthetic vaccine consisting of a tumor-associated glycopeptide antigen and a T-cell epitope for the induction of a highly specific humoral immune response","volume":"44","author":"Dziadek","year":"2005","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2020.110888_bib0415","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1002\/anie.200802102","article-title":"Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response","volume":"47","author":"Westerlind","year":"2008","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2020.110888_bib0420","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1002\/anie.201300390","article-title":"Self-adjuvanting synthetic antitumor vaccines from MUC1 glycopeptides conjugated to T-cell epitopes from tetanus toxoid","volume":"52","author":"Cai","year":"2013","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2020.110888_bib0425","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/anie.201308875","article-title":"Synthetic multivalent glycopeptide-lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells","volume":"53","author":"Cai","year":"2014","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2020.110888_bib0430","doi-asserted-by":"crossref","first-page":"7551","DOI":"10.1002\/anie.200902564","article-title":"A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response","volume":"48","author":"Kaiser","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2020.110888_bib0435","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1158\/2326-6066.CIR-18-0256","article-title":"Reduced breast tumor growth after immunization with a tumor-restricted MUC1 glycopeptide conjugated to tetanus toxoid","volume":"7","author":"Stergiou","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.biopha.2020.110888_bib0440","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/cmdc.201700387","article-title":"Immunization with a synthetic human MUC1 glycopeptide vaccine against tumor-associated MUC1 breaks tolerance in human MUC1 transgenic mice","volume":"12","author":"Stergiou","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.biopha.2020.110888_bib0445","doi-asserted-by":"crossref","first-page":"9977","DOI":"10.1002\/anie.201104529","article-title":"Synthetic antitumor vaccines containing MUC1 glycopeptides with two immunodominant domains-induction of a strong immune response against breast tumor tissues","volume":"50","author":"Gaidzik","year":"2011","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2020.110888_bib0450","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1002\/anie.201509935","article-title":"A synthetic glycopeptide vaccine for the induction of a monoclonal antibody that differentiates between normal and tumor mammary cells and enables the diagnosis of human pancreatic cancer","volume":"55","author":"Palitzsch","year":"2016","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2020.110888_bib0455","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nchembio.2007.25","article-title":"Robust immune responses elicited by a fully synthetic three-component vaccine","volume":"3","author":"Ingale","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2020.110888_bib0460","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1039\/C5SC04039F","article-title":"Mucin architecture behind the immune response: design, evaluation and conformational analysis of an antitumor vaccine derived from an unnatural MUC1 fragment","volume":"7","author":"Mart\u00ednez-S\u00e1ez","year":"2013","journal-title":"Chem. Sci."},{"key":"10.1016\/j.biopha.2020.110888_bib0465","doi-asserted-by":"crossref","first-page":"7154","DOI":"10.1039\/C6CS00858E","article-title":"Principles of mucin structure: implications for the rational design of cancer vaccines derived from MUC1-glycopeptides","volume":"46","author":"Mart\u00ednez-S\u00e1ez","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biopha.2020.110888_bib0470","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1039\/C9SC06334J","article-title":"Synthesis, conformational analysis and in vivo assays of an anti-cancer vaccine that features an unnatural antigen based on an sp2-iminosugar fragment","volume":"11","author":"Bermejo","year":"2020","journal-title":"Chem. Sci."},{"key":"10.1016\/j.biopha.2020.110888_bib0475","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1093\/glycob\/cwj044","article-title":"Chemoenzymatically synthesized multimeric Tn\/STn MUC1 glycopeptides elicit cancer-specific anti-MUC1 antibody responses and override tolerance","volume":"16","author":"Sorensen","year":"2006","journal-title":"Glycobiology"},{"key":"10.1016\/j.biopha.2020.110888_bib0480","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/BF01740902","article-title":"Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvant","volume":"36","author":"Maclean","year":"1993","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2020.110888_bib0485","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1038\/bjc.1996.532","article-title":"A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer","volume":"74","author":"Miles","year":"1996","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2020.110888_bib0490","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1634\/theoncologist.2010-0307","article-title":"Theratope\u00ae Study Group, Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer","volume":"16","author":"Miles","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.biopha.2020.110888_bib0495","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2020.110888_bib0500","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s00262-016-1838-1","article-title":"Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas","volume":"65","author":"Beatty","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.biopha.2020.110888_bib0505","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1586\/erv.09.95","article-title":"Synthetic carbohydrate-based anticancer vaccines","volume":"8","author":"Zhu","year":"2009","journal-title":"Expert Rev. Vaccines"},{"key":"10.1016\/j.biopha.2020.110888_bib0510","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1042\/BST20170400","article-title":"Latest developments in MUC1 immunotherapy","volume":"46","author":"Taylor-Papadimitriou","year":"2018","journal-title":"Biochem. Soc. Trans."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220310805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332220310805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:08:52Z","timestamp":1760098132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332220310805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":102,"alternative-id":["S0753332220310805"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110888","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review on development of MUC1-based cancer vaccine","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2020.110888","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"110888"}}